Health & Biotech
Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.
Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Creso Pharma launches hemp-based product for swine, enters the lucrative livestock market
Health & Biotech
Creso Pharma gets cannabis award in Ontario, increases brand awareness in Canada
Health & Biotech
Creso Pharma secures additional supply of psilocybin, paves the way for future psychedelics products
Health & Biotech
Creso Pharma’s quarterly revenue surges 237%, with the huge US cannabis market now in sight
Health & Biotech
Hot Pot Stocks: Here are 8 ASX plays that have tripled in the last 12 months
Health & Biotech
Creso Pharma makes further push into psychedelic mushrooms, signs agreement with nanotech Sixth Wave
Health & Biotech
Cannabis play Creso Pharma expands tea sales, makes its first move into Africa
Health & Biotech
Creso Pharma targets acquisition company to explore genome sequencing of ‘magic mushrooms’
News
Last Orders: ASX returns from Easter break with a gain
Health & Biotech
It looks like 2021 will be the Year of Cannabis Legalisation in the US
Health & Biotech
Creso Pharma welcomes back experienced cannabis executive as New York legalises weed
Health & Biotech
Creso Pharma to pursue dual listing in USA; announces new psilocybin supplies
Health & Biotech
NY finally on cannabis bandwagon, as ASX-listed Creso Pharma boosts coffers by $18 million
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Creso Pharma to pursue dual listing in USA and announces new psilocybin supplies
Health & Biotech
Here’s why cannabis M&A activity is on the rise and only just getting started in Australia
Health & Biotech